Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCAINAMIDE HYDROCHLORIDE vs NORPACE CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ia antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractory period in atrial and ventricular myocardium.
Class Ia antiarrhythmic agent; decreases myocardial excitability and conduction velocity, and prolongs refractory period by blocking sodium channels.
Treatment of life-threatening ventricular arrhythmias,Atrial fibrillation,Atrial flutter,Paroxysmal supraventricular tachycardia
Treatment of documented life-threatening ventricular arrhythmias (e.g., sustained ventricular tachycardia),Off-label: prevention of atrial fibrillation recurrence, maintenance of sinus rhythm in atrial flutter
Oral: 250-500 mg every 3-6 hours. IV: Loading dose 15-18 mg/kg infused over 25-30 minutes, then maintenance infusion 1-4 mg/min. Maximum total daily dose: 4 g.
Disopyramide controlled-release: 200 mg orally every 12 hours; maximum 400 mg/day.
Terminal elimination half-life: 2.5-5 hours (normal renal function); prolonged to 11-20 hours in renal impairment (e.g., Cr Cl <30 m L/min); clinical context: requires dosing adjustment in renal failure; NAPA half-life: 6-8 hours (normal), up to 40 hours in renal failure.
Terminal elimination half-life: 6-12 hours (normal renal function); prolonged to 12-20 hours in renal impairment. In coronary artery disease, half-life may be extended due to reduced clearance.
Hepatic acetylation via N-acetyltransferase (NAT2) to N-acetylprocainamide (NAPA); CYP2D6 minor pathway.
Primarily hepatic via CYP3A4; also excreted renally.
Renal: ~50-60% unchanged via glomerular filtration and tubular secretion; hepatic metabolism to N-acetylprocainamide (NAPA, active) accounts for ~15-30% of dose, further eliminated renally; biliary/fecal: negligible (<5%).
Renal (50-57% unchanged), hepatic metabolism (30-40%), fecal (<10%). Dose adjustment required for Cr Cl <40 m L/min.
~15-20% bound to serum albumin and alpha-1-acid glycoprotein; low binding minimizes displacement interactions.
30-50% bound to albumin, alpha-1-acid glycoprotein, and lipoproteins.
Vd: 1.5-2.5 L/kg (total body water); extensive tissue distribution (e.g., heart, liver, kidneys); clinical meaning: large Vd indicates substantial extravascular distribution, requiring loading doses for rapid therapeutic effect.
0.6-1.2 L/kg; larger Vd in heart failure (up to 2.0 L/kg) due to reduced tissue binding.
Oral: 75-95% (immediate-release); IM: 100%; sustained-release oral: ~90% (relative to immediate-release).
Oral immediate-release: 70-80%; extended-release: 60-70% (first-pass metabolism). IV: 100%.
Cr Cl 10-50 m L/min: administer every 6-12 hours. Cr Cl <10 m L/min: administer every 8-24 hours. For IV: reduce maintenance infusion rate proportional to Cr Cl.
GFR 30-50 m L/min: 200 mg loading dose, then 100 mg every 12 hours. GFR 15-30 m L/min: 200 mg loading dose, then 100 mg every 24 hours. GFR <15 m L/min: 200 mg loading dose, then 100 mg every 48-72 hours.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: avoid use or reduce dose by 50-75% with monitoring.
Child-Pugh Class B or C: Reduce dose by 50% and titrate carefully; monitor ECGs.
Oral: 15-50 mg/kg/day divided every 3-6 hours. IV: Loading dose 15-18 mg/kg; maintenance 20-80 mcg/kg/min. Maximum: 100 mg/kg/day.
Not recommended for pediatric use; safety and efficacy not established.
Start with lower doses (e.g., 250 mg oral every 6 hours) due to age-related renal decline. Monitor for hypotension and toxicity. Adjust based on Cr Cl.
Initiate at lower dose (e.g., 100 mg every 12 hours of controlled-release) due to increased risk of anticholinergic effects and renal impairment; monitor renal function and QT interval.
May cause severe blood dyscrasias (e.g., agranulocytosis, neutropenia, thrombocytopenia) and drug-induced lupus erythematosus.
May cause widening of QRS complex and prolongation of QT interval, increasing risk of torsade de pointes and sudden death. Avoid use with other drugs that prolong QT interval. Use only for life-threatening arrhythmias.
Monitor CBC regularly; discontinue if blood dyscrasias occur. Prolonged QT interval risk; caution with other QT-prolonging drugs. May exacerbate heart failure or hypotension. Reduce dose in renal impairment.
Can worsen arrhythmias (proarrhythmic); monitor ECG, electrolytes; adjust dose in renal/hepatic impairment; avoid in patients with pre-existing QT prolongation, hypokalemia, or bradycardia.
Complete heart block, second-degree AV block, torsade de pointes, systemic lupus erythematosus, hypersensitivity to procainamide or procaine.
Pre-existing second- or third-degree AV block (unless pacemaker), cardiogenic shock, congenital QT prolongation, concurrent use of other QT-prolonging drugs, hypersensitivity to disopyramide.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes) as hyperkalemia may increase proarrhythmic risk. Alcohol may exacerbate hypotension and cardiac effects.
Avoid grapefruit juice as it may increase disopyramide levels. High-fat meals may delay absorption but do not significantly affect overall bioavailability; take consistently with or without food.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest potential fetal harm. Second/third trimesters: May cause maternal hypotension reducing placental perfusion; use only if clearly needed. Risk of neonatal arrhythmias if used near term.
FDA Pregnancy Category C. First trimester: Evidence of teratogenicity in animal studies (increased fetal resorption and skeletal abnormalities) but no adequate human studies. Second and third trimesters: May cause fetal bradycardia, hypoglycemia, and preterm labor due to beta-blockade effects; avoid use unless benefit outweighs risk.
Present in breast milk in low concentrations; M/P ratio approximately 0.4-0.6. Considered compatible with breastfeeding by American Academy of Pediatrics; monitor infant for bradycardia or hypotension.
Disopyramide is excreted in human breast milk; M/P ratio approximately 0.5-1.0. Limited data suggests low infant exposure but potential for hypoglycemia and bradycardia; caution advised. American Academy of Pediatrics considers disopyramide compatible with breastfeeding with monitoring.
No specific dose adjustments recommended; however, increased volume of distribution and renal clearance in pregnancy may require higher doses or more frequent administration to maintain therapeutic levels. Monitor drug levels closely.
No formal dosing guidelines established. Pregnancy may alter pharmacokinetics (increased volume of distribution and clearance), potentially requiring dose adjustments. Therapeutic drug monitoring is recommended to maintain trough disopyramide levels between 2-5 mcg/m L. Due to proarrhythmic risks, use lowest effective dose and monitor closely.
Procainamide is a Class Ia antiarrhythmic. Monitor for lupus-like syndrome (arthralgias, rash) especially in slow acetylators; screen with ANA titer. Torsades de Pointes risk; monitor QTc. Maintain serum potassium >4.0 m Eq/L. Avoid in myasthenia gravis. Adjust dose in renal impairment.
NORPACE CR (disopyramide phosphate) is a Class Ia antiarrhythmic with strong anticholinergic effects; monitor for urinary retention, constipation, and dry mouth. It has negative inotropic effects and should be avoided in patients with compensated heart failure or cardiomyopathy. Dosage adjustment required in renal impairment (Cr Cl <40 m L/min). Therapeutic drug monitoring recommended (target 2-5 mcg/m L).
Take exactly as prescribed; do not skip doses.,Report any joint pain, rash, fever, or unexplained bruising immediately.,Avoid driving if you experience dizziness or lightheadedness.,Notify your doctor if you have new or worsening shortness of breath or chest pain.,Do not stop taking abruptly; this may cause a serious irregular heartbeat.
Do not crush or chew extended-release tablets; swallow whole.,Take at regular 12-hour intervals to maintain steady drug levels.,Avoid driving or operating machinery until you know how this medication affects you (may cause dizziness or blurred vision).,Report signs of hypoglycemia (sweating, shakiness) in diabetic patients, as disopyramide can lower blood sugar.,Maintain adequate fluid intake to prevent constipation.,Inform all healthcare providers you are taking this medication, especially before surgery or dental procedures.
"Procainamide is a class IA antiarrhythmic that is primarily metabolized by N-acetyltransferase (NAT) and also undergoes CYP2D6-mediated metabolism. Midostaurin, a multikinase inhibitor used for FLT3-mutated AML, is metabolized mainly by CYP3A4. Procainamide can inhibit CYP3A4, reducing the clearance and increasing plasma concentrations of midostaurin, potentially leading to enhanced toxicity including QT prolongation, hepatotoxicity, and myelosuppression."
"Procainamide, a Class Ia antiarrhythmic, prolongs the QT interval by blocking cardiac sodium channels and delaying repolarization. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has been associated with QT prolongation, possibly via inhibition of cardiac hERG potassium channels. Concomitant use increases the risk of excessive QT prolongation, potentially leading to torsade de pointes and other ventricular arrhythmias."
"Procainamide, a class Ia antiarrhythmic agent, prolongs the QT interval by blocking cardiac sodium and potassium channels. Pentamidine, used for Pneumocystis pneumonia, also prolongs the QT interval through inhibition of the rapid delayed rectifier potassium current (IKr). Concomitant use can cause additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with electrolyte disturbances or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCAINAMIDE HYDROCHLORIDE vs NORPACE CR, answered by our medical review team.
PROCAINAMIDE HYDROCHLORIDE is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractory period in atrial and ventricular myocardium.. NORPACE CR is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; decreases myocardial excitability and conduction velocity, and prolongs refractory period by blocking sodium channels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCAINAMIDE HYDROCHLORIDE and NORPACE CR depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCAINAMIDE HYDROCHLORIDE is: Oral: 250-500 mg every 3-6 hours. IV: Loading dose 15-18 mg/kg infused over 25-30 minutes, then maintenance infusion 1-4 mg/min. Maximum total daily dose: 4 g.. The standard adult dose of NORPACE CR is: Disopyramide controlled-release: 200 mg orally every 12 hours; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCAINAMIDE HYDROCHLORIDE and NORPACE CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCAINAMIDE HYDROCHLORIDE is classified as Category A/B. FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest potential fetal harm. Second/third trimesters: May cause maternal hypotension reducing placent. NORPACE CR is classified as Category C. FDA Pregnancy Category C. First trimester: Evidence of teratogenicity in animal studies (increased fetal resorption and skeletal abnormalities) but no adequate human studies. Secon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.